-
公开(公告)号：WO2005104755A3
公开(公告)日：2008-08-21
申请号：PCT/US2005014444
申请日：2005-04-28
Applicant: VAXDESIGN CORP , WARREN WILLIAM L , FAHLENKAMP HEATHER , HIGBEE RUSSELL , KACHURIN ANATOLY , LI CONAN K N , NGUYEN MIKE , PARKHILL ROBERT , SANCHEZ GUZMAN , IRVINE DARRELL J , RANDLOLPH GWENDALYN , NACOHEN NIR , TORBETT BRUCE
Inventor： WARREN WILLIAM L , FAHLENKAMP HEATHER , HIGBEE RUSSELL , KACHURIN ANATOLY , LI CONAN K N , NGUYEN MIKE , PARKHILL ROBERT , SANCHEZ GUZMAN , IRVINE DARRELL J , RANDLOLPH GWENDALYN , NACOHEN NIR , TORBETT BRUCE
CPC classification number: C12N5/0697 , C12N2501/21 , C12N2502/11 , C12N2502/28 , C12N2503/04 , C12N2533/50 , C12N2533/54 , C12N2535/10 , G01N33/5047 , G01N33/5064 , G01N33/5088
Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.
Abstract translation: 本发明涉及构建综合人造免疫系统的方法，其包括适当的体外细胞和组织构建体或其等同物以模拟与哺乳动物中的疫苗相互作用的正常组织。 人工免疫系统可用于测试疫苗候选物在体外的功效，因此可用于加速疫苗开发和测试与免疫系统的药物和化学相互作用。
-
72.发明申请CELLS GENETICALLY MODIFIED TO EXPRESS MARKERS OF FENESTRATION AND USES THEREOF 审中-公开细胞经基因修饰以表达其生物标记物及其用途
公开(公告)号：WO2008014547A1
公开(公告)日：2008-02-07
申请号：PCT/AU2007/001066
申请日：2007-07-31
Applicant: LE COUTEUR, David , COGGER, Victoria
Inventor： LE COUTEUR, David , COGGER, Victoria
CPC classification number: G01N33/5064 , G01N33/5067 , G01N2800/52
Abstract: The present invention relates generally to a population of cells genetically modified to express a detectable marker of fenestration and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of in vitro based screening systems for testing the effectiveness and/or toxicity of potential therapeutic or prophylactic treatment regimes.
Abstract translation: 本发明一般涉及经遗传修饰以表达可检测的开窗标志物的细胞群及其用途。 本发明的细胞可用于各种各样的应用，特别是在用于测试潜在的治疗或预防治疗方案的有效性和/或毒性的基于体外的筛选系统的上下文中。
-
公开(公告)号：WO2007141626A1
公开(公告)日：2007-12-13
申请号：PCT/IB2007001483
申请日：2007-05-29
Applicant: PFIZER PROD INC , GUALBERTO ANTONIO , ROBERTS LUISA MARIA , MELVIN CARRIE LYNN , REPOLLET MADELINE I , CHIANESE DAVID ALLEN , CONNELY MARK CARLE , TERSTAPPEN LEONARDUS WENDELINU
Inventor： GUALBERTO ANTONIO , ROBERTS LUISA MARIA , MELVIN CARRIE LYNN , REPOLLET MADELINE I , CHIANESE DAVID ALLEN , CONNELY MARK CARLE , TERSTAPPEN LEONARDUS WENDELINU
IPC: G01N33/574 , G01N33/50
CPC classification number: G01N33/57496 , G01N30/02 , G01N33/5023 , G01N33/5064 , G01N33/574 , G01N33/57492 , G01N2333/4742 , G01N2333/4745 , G01N2333/71 , G01N2333/91205 , G01N2458/00 , G01N2800/52 , B01D15/3804
Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.
Abstract translation: 公开了用于检测，计数和分析表达胰岛素样生长因子-1受体（IGF-1R）的循环肿瘤细胞的方法。 这些方法可用于癌症筛查和分期，治疗方案的开发以及用于监测治疗反应，癌症复发等的方法。 还提供了促进这种循环肿瘤细胞的检测，计数和分析的测试试剂盒。
-
74.发明申请METHODOLOGIES FOR THE DIAGNOSIS AND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE 审中-公开胃食管反流病的诊断和治疗方法
公开(公告)号：WO2007090124A2
公开(公告)日：2007-08-09
申请号：PCT/US2007/061317
申请日：2007-01-30
Applicant: CHANDRASOMA, Parakrama
Inventor： CHANDRASOMA, Parakrama
CPC classification number: G01N33/57407 , G01N33/5064 , G01N33/56966 , G01N2800/06 , G01N2800/062
Abstract: A novel methodology for diagnosing and treating gastroesophageal reflux disease is provided. These methodologies are based on the discovery of a new disease mechanism called hereinafter "reflux carditis", which is a novel mechanistic view of reflux disease that recognizes cardiac mucosa, which has heretofore been regarded as a normal epithelium in the stomach and an abnormal epithelium in the esophagus, as an abnormal mucosa in both the esophagus and stomach.
Abstract translation: 提供了一种用于诊断和治疗胃食管反流病的新方法。 这些方法基于以下称为“回流性心脏炎”的新型疾病机制的发现，该机制是识别心脏粘膜的回流疾病的新颖的机理观点，其迄今被认为是胃中的正常上皮和异常上皮细胞 食管，食管和胃食管异常粘膜。
-
公开(公告)号：WO2007016159A3
公开(公告)日：2007-07-26
申请号：PCT/US2006029033
申请日：2006-07-25
Applicant: XENOPORT INC , ZERANGUE NOA
Inventor： ZERANGUE NOA
CPC classification number: G01N33/5008 , A61K47/50 , G01N33/5011 , G01N33/5014 , G01N33/5035 , G01N33/5058 , G01N33/5064 , G01N33/6872 , G01N33/9426 , G01N2500/10 , G01N2800/24
Abstract: GAT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the GAT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
Abstract translation: GAT2在脑微血管内皮细胞中一直以高水平表达。 本文公开了用于确定测试材料/分子是否为GAT2转运蛋白的基质和/或由GAT2转运蛋白积极转运的测定法，因此用于跨越血脑屏障的候选底物。 该测定法可用于筛选用于治疗或诊断神经疾病的治疗性，细胞毒性或成像化合物。
-
Patent Agency Ranking
公开(公告)号：WO2007016161A3
公开(公告)日：2007-05-10
申请号：PCT/US2006029039
申请日：2006-07-25
Applicant: XENOPORT INC , ZERANGUE NOA
Inventor： ZERANGUE NOA
CPC classification number: G01N33/5064 , A61K49/0002 , G01N33/5008 , G01N33/5011 , G01N33/5014 , G01N33/5058 , G01N33/566 , G01N33/94 , G01N2333/705 , G01N2500/10
Abstract: OCT3 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the OCT3 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
Abstract translation: OCT3在脑微血管内皮细胞中一直以高水平表达。 本文公开了用于确定测试材料/分子是否为OCT3转运蛋白的底物和/或由OCT3转运蛋白主动转运以及因此用于穿过血脑屏障的候选底物的测定。 该测定可用于筛选用于治疗或诊断神经疾病的治疗剂，细胞毒性剂或成像化合物。
-
公开(公告)号：WO2007016144A3
公开(公告)日：2007-05-10
申请号：PCT/US2006028973
申请日：2006-07-25
Applicant: XENOPORT INC , ZERANGUE NOA
Inventor： ZERANGUE NOA
CPC classification number: G01N33/9426 , G01N33/502 , G01N33/5064 , G01N33/6872
Abstract: OCTN2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the OCTN2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
Abstract translation: OCTN2在脑微血管内皮细胞中一直以高水平表达。 本文公开了用于确定测试材料/分子是否为OCTN2转运蛋白的底物和/或由OCTN2转运蛋白主动转运以及因此穿过血脑屏障的候选底物的测定。 该测定可用于筛选用于治疗或诊断神经疾病的治疗剂，细胞毒性剂或成像化合物。
-
公开(公告)号：WO2007036022A1
公开(公告)日：2007-04-05
申请号：PCT/CA2006/001528
申请日：2006-09-15
Inventor： ABULROB, Abedelanasser , ZHANG, Jianbing
IPC: C07K19/00 , A61K47/00 , A61K31/00 , A61K47/48 , C07K14/195 , C07K14/245 , C07K16/00 , C12N5/00 , C12Q1/00
CPC classification number: A61K49/0058 , A61K47/6849 , A61K49/0032 , C07K14/705 , C07K16/18 , C07K16/28 , C07K2317/22 , C07K2317/569 , C07K2317/77 , G01N33/5064 , G01N33/6854 , G01N2500/04 , G01N2500/10
Abstract: There is disclosed herein subunits and multimers of subunits suitable for use in inducing the transport of one or more cargo substances into a cell and in some instances across a cell. The subunits may have a targeting domain such as an antibody or antibody fragment, a multimerization domain, such as a verotoxin B-subunit mutant scaffold, and a cargo molecule such as a drug or imaging agent, which may be directly linked to the subunit or may be packaged in a liposome, nanoparticle, or the like. In some instances the targeting domain may have affinity for a blood-brain barrier antigen and may be capable of inducing cell mediated transcytosis to facilitate delivery of the cargo molecule across the blood-brain barrier. In some instances the targeting region may have affinity for a cancer antigen and may be capable of inducing cell-mediated endocytosis.
Abstract translation: 本文公开了适用于诱导将一种或多种载体物质运送到细胞中并且在某些情况下跨过细胞的亚基的亚单位和多聚体。 亚基可以具有靶向结构域，例如抗体或抗体片段，多聚化结构域，例如藜芦毒素B亚基突变体支架，以及货物分子，例如药物或成像剂，其可以直接连接到亚基或 可以包装在脂质体，纳米颗粒等中。 在一些情况下，靶向结构域可能对血脑屏障抗原具有亲和力，并且可能能够诱导细胞介导的转胞吞作用以促进货物分子穿过血脑屏障的递送。 在一些情况下，靶向区域可能对癌症抗原具有亲和力，并且可能能够诱导细胞介导的内吞作用。
-
公开(公告)号：WO2007016164A2
公开(公告)日：2007-02-08
申请号：PCT/US2006029042
申请日：2006-07-25
Applicant: XENOPORT INC , ZERANGUE NOA
Inventor： ZERANGUE NOA
IPC: G01N33/50
CPC classification number: G01N33/5064 , A61K47/542 , G01N33/5008 , G01N33/5014 , G01N33/5058 , G01N33/6872 , G01N2500/10
Abstract: CAT1 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the CAT1 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
Abstract translation: CAT1在脑微血管内皮细胞中一直以高水平表达。 本文公开了用于确定测试材料/分子是否为CAT1转运蛋白的底物和/或由CAT1转运体主动转运以及因此用于穿过血脑屏障的候选底物的测定。 该测定法可用于筛选用于治疗或诊断神经疾病的治疗性，细胞毒性或成像化合物。
-
公开(公告)号：WO2006067742A2
公开(公告)日：2006-06-29
申请号：PCT/IB2005/054333
申请日：2005-12-20
Inventor： GRAZIANI, Grazia , VERGATI, Matteo
CPC classification number: G01N33/5064 , C12N5/069 , C12N2503/00 , C12N2503/02 , C12N2510/04 , G01N33/5011
Abstract: The present application is related to immortalized human endothelial cells that maintain the main phenotypic characteristics of the primary cells from which they derive and express one or more TEM markers, in an up- regulated way with respect to said primary cells.
Abstract translation: 本申请涉及永生化的人内皮细胞，其维持原代细胞的主要表型特征，从它们衍生和表达一种或多种TEM标记，以相对于所述原代细胞的上调方式。
-
-
-
-
-
-
-
-
-
Search Results
260
records
(took 0.019 seconds)
